天演藥業 ADAG 深 滬
等待開盤 02-11 09:30:00 美东时间
3.00
+0.330
+12.36%
華盛通- 最 高3.04
- 今 開2.62
- 成交量 9.40万股
- 最 低 2.61
- 昨 收 2.67
- 總市值 1.41亿
- 52周最高 3.19
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 1.30
- 委 比 -29.58%
- 總股本 4713.13万
- 歷史最高 31.83
- 量 比 1.19
- 振 幅 16.10%
- 歷史最低 0.90
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adagene Announces Data Update From Ongoing Phase 1b/2 Study Of Muzastotug + Pembrolizumab In 3L+ MSS CRC Patients Remains On Track For Q1 2026
Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to
01-23 21:21
Adagene Provides Business Update and 2026 Objectives
Adagene Inc. reported unaudited cash of $74.5M as of Dec 31, 2025, providing runway into late 2027. Key 2025 achievements include Phase 1b/2 trial results for muzastotug in MSS CRC, FDA Fast Track designation for muzastotug + pembrolizumab, regulatory alignment with FDA, and initiation of a randomized Phase 2 trial. Strategic partnerships with Sanofi, Third Arc Bio, Exelixis, and ConjugateBio advanced masked antibody therapies. 2026 objectives in...
01-23 13:00
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
Adagene's muzastotug, a next-generation masked anti-CTLA-4 therapy, has been granted Fast Track designation by the FDA for treating microsatellite stable metastatic colorectal cancer patients without liver metastases. The designation is supported by promising clinical data showing efficacy, safety, and durability. Muzastotug uses Adagene's proprietary SAFEbody® technology to enhance tumor targeting while minimizing systemic toxicity. Adagene plan...
2025-12-16 12:00
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Guggenheim Initiates Coverage On Adagene with Buy Rating, Announces Price Target of $9
Guggenheim analyst Paul Jeng initiates coverage on Adagene (NASDAQ:ADAG) with a Buy rating and announces Price Target of $9.
2025-11-24 21:30
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Adagene Inc. and Third Arc Bio, Inc. have entered into a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers targeting unique tumor-associated antigens. Under the terms, Third Arc Bio gains rights to research, develop, and commercialize two candidate molecules worldwide, while Adagene receives an upfront payment of $5 million, up to $840 million in milestones, an...
2025-11-13 12:00
Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDAPatients randomized to either 10 or 20 mg/kg of muzastotug, in combination
2025-10-31 19:02
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
2025-09-19 09:18
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Adagene Inc. has amended its 2021 collaboration with Exelixis to develop an antibody-drug conjugate (ADC) targeting a solid tumor using its proprietary SAFEbody technology, enabling tumor-specific targeting with reduced side effects. Adagene is eligible for milestones and royalties, and its SAFEbody platform, designed to bind preferentially to tumor cells while masking in healthy tissues, has shown promise in clinical studies with its lead candid...
2025-09-16 12:00
